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Background: The common comorbidities associated with COPD include, among others, 
anxiety, depression, and insomnia, for which the typical treatment involves the use of benzo-
diazepines (BZD). However, these medicines should be used with extra caution among COPD 
patients, since treatment with traditional BZD may compromise respiratory function. 
Aims: This study investigated the use of BZD among persons suffering from COPD by analyzing 
three relevant indicators: 1) the sum of defined daily doses (DDD); 2) the number of prescribers 
involved; and 3) the number of different types of BZD used. 
Data and methods: The study builds on a linkage of national prescription data and patient–
administrative data, which includes all Norwegian drug prescriptions to persons hospitalized 
with a COPD diagnosis during 2009, amounting to a total of 5,380 observations. Regression 
techniques were used to identify the patients and the clinical characteristics associated with 
BZD use. 
Results: Of the 5,380 COPD patients treated in hospital during 2009, 3,707 (69%) were dis-
pensed BZD during the following 12 months. Moreover, they were dispensed on average 197.08 
DDD, had 1.22 prescribers, and used 0.98 types of BZD during the year. Women are more 
likely to use BZD for all levels of BZD use. Overnight planned care not only increases the risk 
of BZD use (DDD), but also the number of prescribers and the types of BZD in use.
Conclusion: In light of the high levels of BZD prescription found in this study, especially 
among women, it is recommended that general practitioners, hospital specialists, and others 
treating COPD patients should aim to acquire a complete picture of their patients’ BZD medica-
tion before more is prescribed in order to keep the use to a minimum. 
Keywords: benzodiazepine use, defined daily doses, number of prescribers, patient and clinical 
characteristics, Norway, population based study
Introduction
COPD is a major cause of chronic morbidity and mortality throughout the world. 
In 2001, COPD was the fifth leading cause of death in high-income countries, and it 
was also estimated to be a leading cause of disability-adjusted life years.1 The com-
mon comorbidities associated with COPD include, among others, anxiety, depression, 
and insomnia, for which the typical treatment involves the use of benzodiazepines 
(BZD). However, these medicines should be used with extra caution among COPD 
patients, since treatment with traditional BZD may compromise respiratory function.2,3 
The potential adverse respiratory effects of BZD in COPD may also be higher in 
older adults, given their altered pharmacokinetics that increase the BZD half-life.4 
As such, joint American Thoracic Society/European Respiratory Society guidelines 
recommend that hypnotics, such as BZD, be avoided in patients with severe COPD.5 
Yet, BZD are still widely prescribed despite the adverse pulmonary effects that could 
potentially lead to poor outcomes in the COPD population.3 Moreover, overmedication 
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and unnecessary drug use is a risk when the medication 
regimen becomes too complex.6 It is therefore important 
to understand the scope and nature of BZD use in COPD. 
Yet, few studies are available that actually investigate the 
dispensing of these medicines to persons with COPD and 
the relevant patient and clinical characteristics associated 
with it. This study thus combines national prescription and 
patient–administrative data to study the use of BZD in the 
Norwegian COPD population. 
In a review of the research field on anxiety and depres-
sion in COPD, Maurer et al7 found that in stable COPD, the 
prevalence of clinical depression ranged between 10% and 
42%, while that of anxiety ranged between 10% and 19%. 
COPD patients are faced with major physical impairment 
and embarrassing symptoms such as dyspnea and produc-
tive cough, and their quality of life is significantly affected 
through restrictions of daily living and recreational activi-
ties, as well as via impairment of social and psychological 
functioning.8 Adding to this, several treatment modalities 
commonly used in the treatment of COPD can cause nervous 
system side effects that can put the patient at higher risk for 
developing psychiatric comorbidities, as they may cause feel-
ings of restlessness, apprehension, anxiety, fear, irritability, 
and mood changes.9 
COPD patients are also more likely to suffer from sleep 
abnormalities, which may take the form of longer latency to 
sleep onset, more frequent arousals and awakenings, more 
frequent stage changes, and poorer sleep efficiency than 
normal individuals.10 Over 50% of COPD patients report a 
long sleep latency, frequent arousals during the night, and/
or general insomnia.2 Insomnia tends to be more prevalent 
and severe with advanced disease, roughly correlating with 
the extent of underlying lung disease.10 An analysis of a large 
COPD database revealed that 21.4% of the listed COPD 
patients were diagnosed with and treated for insomnia, as 
compared to only 7.2% of non-COPD patients.11 Sleep dis-
turbance in patients with chronic airflow limitation is found 
to be consistently associated with reduced quality of life.8 
The poor sleep quality in COPD patients is due to cough, 
excess mucous production, and frequent arousals from sleep 
caused by hypercapnia, as well as to secondary medications 
used to manage the lung disease.2 
Hence, from both a psychiatric and sleep deprivation 
perspective, one should expect that COPD patients comprise 
a group of high consumers of BZD, but the potential adverse 
respiratory effects of BZD in COPD suggest the cautious use 
of these drugs. Estimates that indicate thresholds for increase 
in risk with low dose treatment would certainly be informative 
in a presumed high risk population, but such safety data for 
BZD in patients with COPD are limited.12 In a study of the 
effects of 1.5–2 mg dose lorazepam on respiratory func-
tion in COPD, a 20% decrease in minute ventilation due to 
decreased tidal volume was found.13 Moreover, the results 
showed a 10%–15% reduction in a number of respiratory 
muscle functional parameters after a single dose, including 
negative effects on diaphragmatic endurance. In another study 
by Cohn et al14 it was noted that a 30 mg dose of flurazepam 
resulted in a decreased tidal volume in mild COPD patients, 
and a decrease in oxygen saturation. A third study reported 
that a single oral dose of diazepam to patients with moderate 
to severe COPD resulted in a significant decrease in ventila-
tor drive in response to hypercapnia and mouth occlusion.15 
Studies have also found that 0.25 mg of triazolam significantly 
decreased the arousal threshold to airway occlusion in both 
normal subjects and those with severe obstructive sleep apnea 
syndrome.16,17 In a recent study from 2014,12 which set out to 
evaluate the safety of BZD and opioids in patients with severe 
COPD, concurrent BZD and opioids in lower doses (#0.3 
defined daily doses [DDD]/day) were not associated with 
increased admissions or mortality, whereas BZD and opioids 
in higher doses (.0.3 DDD/day) might increase mortality. 
While several studies have thus described the adverse 
pulmonary events of BZD in COPD, there is still a lack of 
research on the use of BZD among COPD patients. The 
present study builds on a linkage of national prescription 
data and patient–administrative data, which include all 
Norwegian drug prescriptions to persons hospitalized with a 
COPD diagnosis during 2009, amounting to a total of 5,380 
observations. Regression techniques were used to identify 
patient and clinical characteristics associated with BZD 
use. Three relevant indicators of BZD use and consumer 
behavior were analyzed: 1) the sum of DDD; 2) the number 
of prescribers involved; and 3) the number of different types 
of BZD used (ie, different Anatomical Therapeutic Chemical 
[ATC] classification codes). 
Data and methods
We built our analysis on the assumption that BZD use and 
consumer behavior among COPD patients can be modeled 
as a function of patient characteristics (age, sex, and whether 
the patient died during the period of observation), clinical 
characteristics (emergency admissions, elective admissions, 
day treatments, in-hospital treatments, polyclinic consulta-
tions, length of stay, and private hospital treatment), and the 
geographic region where the patient is treated. This can be 
expressed in a more compact form as Equation 1, where y 
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1697
Benzodiazepine use in COPD
is BZD use/consumer behavior, and P, C, and G are vectors 
that describe the effect of patient characteristics, clinical 
characteristics, and geography:
 y = f (P, C, G) (1)
The empirical basis for the analysis is individual data 
from the Norwegian Prescription Database (NorPD) that 
were linked to the Norwegian Patient Register (NPR). Both 
the NorPD and NPR include a unique personal identifica-
tion number, which makes it possible to link data from the 
two registers. 
The NorPD contains information about all drugs pre-
scribed (reimbursed or not) and dispensed at pharmacies to 
individual patients living outside institutions – ie, ambulant 
care. Unlicensed drugs are also included, but drugs sold 
over the counter are not recorded in the NorPD. The register 
records the birth date, month/year of death, sex, and place of 
residence of the patient, as well as the following information 
for the prescribed drug: brand name; strength; pharmaceuti-
cal form and pack size; number of packs; the World Health 
Organization’s ATC classification codes; the number of 
DDD; prescription category; reimbursement code; intended 
use and prescribed dose; dispensing date and price (pharmacy 
retail price); and the geographic location of the pharmacy. 
The NPR covers nearly all inpatient and outpatient 
hospital care in Norway, and it is owned, funded, and run 
by the government. Data on the patient’s age, sex, residence, 
hospital, department, diagnosis/diagnoses, and surgical 
procedure(s), as well as dates of admission, discharge, and 
procedure(s) are included in the registry.
The information on the use of medicine is generated for 
each patient by aggregating information on the prescrip-
tions of the relevant drugs during the 12 months following 
the patient’s last hospital discharge in 2009. A total of 
5,380 patients where registered with a primary diagnosis of 
COPD, defined as those with one or more of the following 
International Classification of Diseases and Related Health 
Problems (ICD-10) main diagnoses: 
•	 J41: Simple and mucopurulent chronic bronchitis
•	 J42: Unspecified chronic bronchitis
•	 J43: Emphysema
•	 J44: Other chronic obstructive pulmonary disease.
The types of BZD included in the study were clonazepam, 
diazepam, oxazepam, alprazolam, nitrazepam, flunitrazepam, 
and midazolam. In addition, we also included the so-called 
BZD-like hypnotics, commonly termed z-hypnotics. Despite 
the fact that these types of drugs imply different bindings to 
the BZD receptor, clinical experience shows that they can 
have similar effects, and may thus cause the same problems 
in terms of adverse effects, dependency, abuse, and with-
drawal symptoms as those experienced with BZD.18 Of the 
z-hypnotics, only zolpidem and zopiclone are registered for 
use in Norway, and they are the ones included in this study. 
We used number of DDD to measure the volume dis-
pensed of the types of medicine in question. A DDD is 
defined as the assumed average maintenance dose per day 
for a drug used for its main indication in adults. The DDD 
are determined on the basis of evaluation of the international 
use of the substance in question, bearing in mind that national 
therapy traditions (indications, dosages) often differ greatly. 
Each DDD should therefore be regarded as a technical mea-
suring unit.19 In addition to consumption, we also included the 
number of prescribers and the number of different medica-
tions (different ATC codes) as outcome measures. 
Multivariate regression is used to estimate the relationship 
between our dependent and independent variables. The distri-
butions of all of our three dependent variables are skewed to 
the right in its original form. Most COPD patients either use 
no BZD, or in moderate quantities, and most COPD patients 
are prescribed BZD from only one or two prescribers, if they 
are prescribed any at all. Moreover, most COPD patients use 
only one type of BZD, if at all. There is, however, a sub-
stantial group that deviates from this pattern, characterized 
by the dispensing of higher quantities of DDD, the use of 
multiple BZD prescribers, and the use of multiple types of 
BZD. To distinguish between these groups in our analysis, 
and to avoid the inherent problems associated with skewed 
distributions, we made use of multinomial logistic regression. 
All three of our dependent variables are therefore coded into 
one of four groups, where the base group (the group that all 
others are compared to) is the one with no BZD dispensing 
(ie, zero DDD, prescribers, and types of BZD). The coding 
of the other groups for DDD is as follows: 1) 1–100 DDD; 
2) 101–400 DDD; and 3) more than 400 DDD during the 
year. For the number of prescribers the coding is as follows: 
1) 1–2 prescribers; 2) 3–5 prescribers; and 3) more than five 
prescribers. For BZD types, the coding is as follows: 1) one 
type; 2) 2–3 types; and 3) more than three types. We choose 
to have our results reported as the relative risk ratios. 
Results
Of the 5,380 COPD patients treated in hospital during 2009, 
3,707 were dispensed BZD during the following 12 months. 
This is close to 69% of the patients. Moreover, they were dis-
pensed an average of 197.08 DDD, they had 1.22 prescribers, 
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and used 0.98 types of BZD during the year. There were 
no missing observations for the variables included in our 
analysis (Table 1).
Tables 2–4 present the results from the regression analysis 
of BZD use. As could be expected, the patient characteristics 
are important in explaining BZD use among COPD patients. 
First of all, male patients had a lower consumption of BZD 
than did the female patients for all levels of dispensing; they 
also consulted with fewer prescribers (Table 3) and used 
fewer medication types than women (Table 4). The finding 
that BZD are prescribed more frequently to women than to 
men is also supported by numerous other studies.20–22 
Age has been found to be a strong predictor of BZD use 
for the general population, and the same is also found for 
the COPD patients in our study, although the effect is not 
significant for the group with more than 400 DDD.21–23 The 
same pattern is also evident for the number of prescribers 
(Table 3) and types of BDZ (Table 4); however, only the 
relative risk of using one BZD attains a conventional sig-
nificance level.
Of the clinical characteristics, elective in-hospital treat-
ment appears to be of particular relevance for the dispensing 
of BZD. In the model, this variable measures the number of 
contacts of this type. Each elective in-hospital stay was also 
associated with the use of more prescribers and medication 
types. The same relationships hold for daytime acute care 
and, to some extent, overnight acute care as well, although 
on a smaller scale, and only for 6+ prescribers and the group 
of 2–3 medication types. Length of stay does not have sig-
nificant effects on BZD use.
The analysis also uncovers some geographic variations in 
BZD use. First of all, the results indicate that patients from 
the northern region are distinguished by a lower prevalence 
of patients in the group with the highest consumption (.400 
DDD) compared to the reference group – ie, those in the 
southeast region. The north also had lower prevalence rates 
in the group with only one prescriber, but a significantly 
higher relative risk of belonging to the next group with 2–5 
prescribers. The north also had a reduced risk of belonging 
to the group using 2–3 types of BZD. 
Discussion
BZD are known to cause problems in some patients with 
obstructive lung disease, and several studies documenting 
such effects are summed up by George and Bayliff.2 Safe 
pharmacological treatment of insomnia must include consid-
eration for whether the hypnotic could potentially exacerbate 
the already present breathing problems in COPD patients.3 
Extra caution is required for persons at increased risk of 
adverse respiratory effects, such as those with advanced 
disease. Also, the side effects of cognitive impairment and 
anterograde amnesia make BZD a poor choice for the elderly 
COPD population.2,3 Given these complications, it gives 
cause for concern that as much as 69% of patients treated 
for COPD also receive BZD. Earlier studies have shown that 
this is, almost without exception, considerably higher than 
all other somatic diagnoses and also higher than the average 
for patients treated at psychiatric hospitals where the similar 
figure is 52%.24
Turning to the covariates, and starting with the patient 
characteristics, our results are in accordance with the numer-
ous studies that have documented that psychotropic drugs are 
prescribed more frequently to women than to men.21,22 One 
possible explanation offered for this difference is that it may 
simply reflect a larger prevalence of depression in females 
than in males. Also, it may be that women are more likely to 
seek care for conditions that are treatable by these drugs.21 
Another possibility is that there is bias within the medical 
profession that results in women receiving a disproportionate 
number of prescriptions for psychotropic drugs. According to 
this hypothesis, physicians may be predisposed to diagnosing 
neurotic disturbances in women and to medicate women who 
are experiencing psychological disturbances.20 
The use of BZD in elderly patients calls for particular 
attention, since the benefits are the least and the risks the 
greatest for this age group.25 The elderly have a higher risk 
of dependence and are more sensitive to the adverse effects, 
such as memory problems, daytime sedation, impaired 
Table 1 Descriptive statistics
Variable Mean Standard deviation
DDDa 1.279 1.068
number of prescribersa 0.830 0.668
number of medication typesa 0.939 0.757
Menb 0.451 0.498
age 68.736 11.087
Death of patientb 0.107 0.309
Overnight elective care 0.284 0.522
Polyclinic elective care 0.024 0.160
Overnight acute care 0.069 0.260
Daytime acute care 0.017 0.232
Polyclinic acute care 0.822 0.745
Days in treatment 2.797 6.657
Western norwayb 0.158 0.365
Mid-norwayb 0.123 0.329
northern norwayb 0.125 0.331
nonregion/privateb 0.031 0.174
Notes: aCategorical variables with values 0–3; bdummy variables.
Abbreviation: DDD, defined daily doses.
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coordination, and increased risks of motor vehicle accidents, 
falls, hip fractures, and dementia.26–28
It has been documented that many patients are first 
introduced to BZD during hospitalization.29 Typically, BZD 
initiation may result from short-term insomnia, which may 
again be due to various aspects associated with hospitaliza-
tion, such as the effects of illness, new medications, and 
environmental factors, including noise and disruption of 
usual sleeping schedules and anxiety.30 While the associa-
tion between hospitalization and BZD initiation has been 
well explored, we have found few other studies that have 
linked BZD use to type and frequency of hospitalization. 
In our study, BZD use was first and foremost related to 
elective treatment. The most likely explanation is that that 
the establishment or renewal of long-term BZD treatments 
will happen in an elective setting, as part of an established 
medication regimen, while short-term BZD treatments are 
more likely prescribed in an acute setting. It is, however, a 
danger that the medication regimen becomes too complex 
when patients receive prescriptions both in a hospital setting 
and from their general practitioner. Although we cannot 
establish with certainty if this is indeed the case here, we can 
see that the increase in BZD volume is also accompanied by 
significant increases in both the number of prescribers and 
the types of BZD used. 
Several studies have investigated the effect of length of 
stay on BZD use, but the relationship remains unclear; some 
studies have found BZD use to be associated with longer 
duration of hospitalization, while others have documented 
no effect of length of stay on the prevalence of BZD use at 
discharge.30,31 Length of stay was not significantly associated 
with DDD in our study. 
Earlier studies have documented geographic variations 
in the consumption of anxiolytics and z-hypnotics for 
Norway.24,32 The pattern is, however, less clear when studying 
only COPD patients, but for the northern region, there was 
still significantly less use of BZD and less combinations of 
medication types used. 
Table 2 Dispensing of BZD measured in DDD for COPD patients (relative risk ratios)
Variables 1–100
DDD
101–400
DDD
401+
DDD
Men 0.626*** 0.622*** 0.505***
(0.541–0.723) (0.539–0.717) (0.426–0.599)
age 1.010*** 1.028*** 0.997
(1.003–1.017) (1.021–1.035) (0.990–1.005)
Death of patient 1.631*** 0.918 0.436***
(1.289–2.065) (0.715–1.179) (0.303–0.626)
Overnight planned care 1.305*** 1.244** 1.536***
(1.074–1.586) (1.021–1.517) (1.229–1.919)
Polyclinic planned care 1.225 1.427 0.853
(0.771–1.945) (0.912–2.234) (0.472–1.542)
Overnight acute care 1.310 1.347 1.497
(0.821–2.089) (0.845–2.147) (0.884–2.534)
Daytime acute care 2.741*** 2.659*** 2.377**
(1.402–5.359) (1.358–5.210) (1.135–4.979)
Polyclinic acute care 1.059 0.976 0.904
(0.942–1.191) (0.863–1.104) (0.777–1.052)
Days in treatment 1.002 0.996 1.004
(0.984–1.020) (0.978–1.015) (0.983–1.025)
Western norway 0.861 0.884 0.933
(0.701–1.059) (0.722–1.083) (0.738–1.178)
Mid-norway 0.992 1.121 1.116
(0.787–1.252) (0.896–1.404) (0.860–1.448)
northern norway 0.950 0.868 0.591***
(0.765–1.181) (0.697–1.081) (0.443–0.787)
nonregion/private 0.852 1.017 0.605
(0.470–1.544) (0.567–1.825) (0.315–1.159)
Constant 0.438*** 0.155*** 0.888
(0.268–0.714) (0.0937–0.256) (0.509–1.550)
Observations 5,380 5,380 5,380
Notes: These values all represent relative risk rations with 95% confidence intervals in parentheses. **P,0.05; ***P,0.01.
Abbreviations: BZD, benzodiazepines; DDD, defined daily doses.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1700
halvorsen and Martinussen
Table 3 number of BZD prescribers for COPD patients (relative risk ratios)
Variables 1 prescriber 2–5 prescribers 6+ prescribers
Men 0.599*** 0.563*** 0.636*
(0.531–0.677) (0.466–0.681) (0.380–1.064)
age 1.017*** 1.002 0.982
(1.011–1.023) (0.994–1.011) (0.961–1.004)
Death of patient 1.197* 0.518*** 0.210**
(0.968–1.480) (0.357–0.750) (0.0472–0.935)
Overnight planned care 1.252*** 1.616*** 2.005**
(1.056–1.485) (1.266–2.062) (1.026–3.916)
Polyclinic planned care 1.319 0.875 3.33e-06
(0.888–1.960) (0.457–1.679) –
Overnight acute care 1.384 1.120 3.895**
(0.923–2.076) (0.622–2.017) (1.294–11.72)
Daytime acute care 2.621*** 2.549** 3.610***
(1.359–5.055) (1.205–5.392) (1.684–7.740)
Polyclinic acute care 1.032 0.814** 0.503**
(0.932–1.143) (0.676–0.981) (0.254–0.996)
Days in treatment 0.996 1.020* 0.966
(0.980–1.012) (0.999–1.042) (0.914–1.020)
Western norway 0.913 0.747** 0.956
(0.769–1.082) (0.559–0.998) (0.446–2.048)
Mid-norway 0.987 1.468*** 1.868*
(0.812–1.200) (1.108–1.946) (0.914–3.815)
northern norway 0.702*** 1.551*** 1.425
(0.580–0.848) (1.196–2.012) (0.682–2.977)
nonregion/private 0.878 0.772 0.420
(0.529–1.457) (0.386–1.542) (0.0686–2.567)
Constant 0.673* 0.392*** 0.194*
(0.445–1.017) (0.208–0.738) (0.0373–1.004)
Observations 5,380 5,380 5,380
Notes: These values all represent relative risk rations with 95% confidence intervals in parentheses. *P,0.1; **P,0.05; ***P,0.01; –Indicates insufficient data.
Abbreviation: BZD, benzodiazepines.
There are several limitations in our study. First of all, our 
data prevented us from controlling for COPD severity. Obvi-
ously, the relationship between severity and BZD use is of 
great concern, since the potential adverse respiratory effects 
of BZD in COPD is related to severity. Second, our data 
also lack information on indications for BZD prescriptions, 
which means that we were unable to distinguish BZD use 
for insomnia from that related to psychiatric reasons. Third, 
without established safety data for BZD use in patients with 
COPD, it becomes difficult to assess the scope of problematic 
use in our data. 
However, in contrast with other similar studies of BZD 
use in COPD, our study was able to build on patient–admin-
istrative data that cover every patient contact with hospital 
in the country, rather than only a small sample of patients. 
Thus, we could analyze the whole COPD population, which 
eliminates common concerns related to representativeness, 
etc. Moreover, this study adds to the previous research 
by investigating the role of clinical characteristics for 
BZD use. 
Conclusion
The high consumption of BZD in COPD found in this study 
gives cause for concern. The reported effects on respiratory 
function in other studies suggest that there are significant 
safety concerns associated with the use of BZD in COPD.12–17 
Also, adverse effects of BZD on cognitive function suggest 
that they may not be the best choice for use in elderly COPD 
patients who may be at increased risk for falls and fractures.3 
There is clearly a need for further studies to identify the 
causes of these elevated levels of BZD dispensing and to 
find alternative treatment strategies to address the sleep 
abnormalities, anxiety, and depression that follow from the 
exacerbation of this disease, without exposing the patients 
to the risks associated with the BZD. Future research would 
be well advised to take advantage of the possibilities that lie 
in the increased access to person-identifiable health registers 
to systematically address these research issues.
Given the unclear role of BZD in the management of 
refractory breathlessness, this study supports the sugges-
tion that BZD should not be the first-line treatment for 
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Table 4 number of different types of BZD prescribed to COPD patients (relative risk ratios)
Variables 1 type of BZD 2–3 types of BZD 4+ types of BZD
Men 0.671*** 0.462*** 0.674
(0.591–0.761) (0.397–0.538) (0.367–1.240)
age 1.019*** 1.006* 0.976*
(1.013–1.025) (0.999–1.013) (0.951–1.002)
Death of patient 1.015 1.137 0.351
(0.812–1.269) (0.883–1.464) (0.0769–1.605)
Overnight planned care 1.148 1.650*** 2.600***
(0.960–1.373) (1.354–2.011) (1.369–4.938)
Polyclinic planned care 1.167 1.303 0.906
(0.767–1.776) (0.819–2.073) (0.139–5.906)
Overnight acute care 1.148 1.881*** 1.20e-06
(0.750–1.757) (1.190–2.974) –
Daytime acute care 2.722*** 2.382** 3.396***
(1.408–5.264) (1.181–4.804) (1.538–7.502)
Polyclinic acute care 1.015 0.914 1.310*
(0.913–1.129) (0.799–1.045) (0.967–1.774)
Days in treatment 1.004 0.993 1.003
(0.988–1.021) (0.975–1.011) (0.913–1.102)
Western norway 0.932 0.821* 0.444
(0.780–1.114) (0.663–1.018) (0.154–1.281)
Mid-norway 1.053 1.126 0.786
(0.860–1.289) (0.891–1.423) (0.297–2.075)
northern norway 0.898 0.705*** 0.821
(0.742–1.087) (0.554–0.898) (0.335–2.014)
nonregion/private 0.871 0.782 0.583
(0.514–1.476) (0.437–1.400) –
Constant 0.464*** 0.653* 0.120**
(0.301–0.714) (0.394–1.081) (0.0202–0.712)
Observations 5,380 5,380 5,380
Notes: These values all represent relative risk rations with 95% confidence intervals in parentheses. *P,0.10; **P,0.05; ***P,0.01; – Indicates insufficient data.
Abbreviation: BZD, benzodiazepines.
breathlessness in those with respiratory failure. In light of 
the high levels of BZD prescription found in this study, 
especially among women, it is recommended that general 
practitioners, hospital specialists, and others treating COPD 
patients should aim to acquire a complete picture of their 
patients’ BZD medication before more is prescribed in order 
to keep the use to a minimum.
Acknowledgment
The article is based on research funded by the Norwegian 
Research Council (grant number 196 373). 
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and 
regional burden of disease and risk factors, 2001: systematic analysis of 
population health data. Lancet. 2006;367(9524):1747–1757.
2.  George CF, Bayliff CD. Management of insomnia in patients with chronic 
obstructive pulmonary disease. Drugs. 2003;63(4):379–387.
 3. Roth T. Hypnotic use for insomnia management in chronic obstructive 
pulmonary disease. Sleep Med. 2009;10(1):19–25.
 4. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among 
older adults with chronic obstructive pulmonary disease: a population-
based cohort study. Drugs Aging. 2013;30(3):183–192.
 5. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diag-
nosis and treatment of patients with COPD: a summary of the ATS/
ERS position paper. Eur Respir J. 2004;23(6):932–946.
 6. Frazier SC. Health outcomes and polypharmacy in elderly individuals: 
an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.
 7. Maurer J, Rebbapragada V, Borson S, et al; ACCP Workshop Panel on 
Anxiety and Depression in COPD. Anxiety and depression in COPD: 
current understanding, unanswered questions, and research needs. 
Chest. 2008;134(4 Suppl):43S–56S.
 8. van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, 
Schadé E. Prevalence of comorbidity in patients with a chronic airway 
obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3): 
287–293.
 9. Putman-Casdorph H, McCrone S. Chronic obstructive pulmonary disease, 
anxiety, and depression: state of the science. Heart Lung. 2009;38(1): 
34–47.
 10. Douglas N. Chronic obstructive pulmonary disease. In: Kryger M, Roth T, 
Dement WC, editors. Principles and Practice of Sleep Medicine. 
Philadelphia, PA: WB Saunders; 2000:965–973.
 11. Vallarino CR, Mini L. Prevalence of insomnia in patients with chronic 
obstructive pulmonary disease in a large database. Value Health. 
2005;8:322.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1702
halvorsen and Martinussen
 12. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. 
Safety of benzodiazepines and opioids in very severe respiratory dis-
ease: national prospective study. BMJ. 2014;348:g445.
 13. Jolly E, Aguirre L, Jorge E, Luna C. [Acute effect of lorazepam on respi-
ratory muscles in stable patients with chronic obstructive pulmonary 
disease]. Medicina (B Aires). 1996;56(5 Pt 1):472–478. Spanish.
 14. Cohn MA, Morris DD, Juan D. Effects of estazolam and flurazepam 
on cardiopulmonary function in patients with chronic obstructive pul-
monary disease. Drug Saf. 1992;7(2):152–158.
 15. Beaupré A, Soucy R, Phillips R, Bourgouin J. Respiratory center out-
put following zopiclone or diazepam administration in patients with 
pulmonary disease. Respiration. 1988;54(4):235–240.
 16. Berry RB, McCasland CR, Light RW. The effect of triazolam on the 
arousal response to airway occlusion during sleep in normal subjects. 
Am Rev Respir Dis. 1992;146(5 Pt 1):1256–1260.
 17. Berry RB, Kouchi K, Bower J, Prosise G, Light RW. Triazolam in 
patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1995; 
151(2 Pt 1):450–454.
 18. Sandvik P. Finnes det fornuftig bruk av benzodiazepiner? Utposten. 
2008;37:14–18. Norwegian.
 19. Sakshaug S, Strøm H, Blix HS, Litleskare I, Rønning M, Granum T. 
Drug Consumption in Norway 2007–2011. A Statistical Presentation of 
the Drug Consumption in Norway during the Years 2007–2011 Based on 
Sales Data from Wholesalers. Oslo, Norway: The Norwegian Institute 
of Public Health; 2012.
 20. Morabia A, Fabre J, Dunand JP. The influence of patient and physician 
gender on prescription of psychotropic drugs. J Clin Epidemiol. 1992; 
45(2):111–116.
 21. Kassam A, Patten SB. Hypnotic use in a population-based sample of over 
thirty-five thousand interviewed Canadians. Popul Health Metr. 2006; 
4:15.
 22. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Clinical factors 
influencing the prescription of antidepressants and benzodiazepines: 
results from the European study of the epidemiology of mental disorders 
(ESEMeD). J Affect Disord. 2008;110(1–2):84–93.
 23. Halvorsen T, Martinussen PE. The geography of chronic obstructive 
pulmonary disease: a population-based study of Norway. Soc Sci Med. 
2014;111:25–34.
 24. Haugan T, Halvorsen T, Martinussen PE. Bruk av Vanedannende 
Legemidler i Norge; i Befolkning Generelt, Og Blant Pasienter Utskre-
vet Fra Sykehus. Trondheim, Norway: SINTEF; 2011. Norwegian.
 25. Bain KT. Management of chronic insomnia in elderly persons. Am J 
Geriatr Pharmacother. 2006;4(2):168–192.
 26. Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A. Postural 
instability and consequent falls and hip fractures associated with use of 
hypnotics in the elderly: a comparative review. Drugs Aging. 2005;22(9): 
749–765.
 27. Bogunovic OJ, Greenfield SF. Practical geriatrics: Use of benzodiaz-
epines among elderly patients. Psychiatr Serv. 2004;55(3):233–235.
 28. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and 
risk of dementia: prospective population based study. BMJ. 2012;345: 
e6231.
 29. Stuffken R, van Hulten RP, Heerdink ER, Movig KL, Egberts AC. 
The impact of hospitalisation on the initiation and long-term use of 
benzodiazepines. Eur J Clin Pharmacol. 2005;61(4):291–295.
 30. Bell CM, Fischer HD, Gill SS, et al. Initiation of benzodiazepines 
in the elderly after hospitalization. J Gen Intern Med. 2007;22(7): 
1024–1029.
 31. Lagnaoui R, Moore N, Longy-Boursier M, Baumevieille M, Bégaud B. 
Benzodiazepine use in patients hospitalized in a department of internal 
medicine: frequency and clinical correlates. Pharmacoepidemiol Drug 
Saf. 2001;10(6):531–535.
 32. Rønning M, Berg C, Furu K, et al. Reseptregisteret 2005–2009. Tema: 
Vanedannende Legemidler. Nydalen, Norway: Folkehelseinstituttet; 
2010:2. Norwegian.
